analytical verification raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
The plasma is strongly collisional, so that the collision time scale is shorter than the other characteristic time scales in the system, and the particle distributions are therefore close to Maxwellian. The resistivity due to these collisions is small. In particular, the typical magnetic diffusion time over any length scale present in the system must be longer than any time scale of interest. The relevant length scales are much longer than the ion skin depth and the Larmor radius perpendicular to the field, sufficiently long scales along the field to ignore Landau damping, and time scales much longer than the ion gyration time (that is, the system is smooth and slowly evolving).
They invented a stochastic corrector model that assumed that replicative templates compete within compartments, and selective values of these compartments depend on the internal composition of templates. Numerical simulations showed that when stochastic effects are taken into account, compartmentalization is sufficient to integrate information dispersed in competitive replicators without the need for hypercycle organization. Moreover, it was shown that compartmentalized hypercycles are more sensitive to the input of deleterious mutations than a simple package of competing genes. Nevertheless, package models do not solve the error threshold problem that originally motivated the hypercycle.
Inverse gas chromatography is a physical characterization analytical technique that is used in the analysis of the surfaces of solids. Inverse gas chromatography or IGC is a highly sensitive and versatile gas phase technique developed over 40 years ago to study the surface and bulk properties of particulate and fibrous materials. In IGC the roles of the stationary (solid) and mobile (gas or vapor) phases are inverted from traditional analytical gas chromatography (GC); IGC is considered a materials characterization technique (of the solid) rather than an analytical technique (of a gas mixture). In GC, a standard column is used to separate and characterize a mixture of several gases or vapors. In IGC, a single standard gas or vapor (probe molecule) is injected into a column packed with the solid sample under investigation. During an IGC experiment a pulse or constant concentration of a known gas or vapor (probe molecule) is injected down the column at a fixed carrier gas flow rate. The retention time of the probe molecule is then measured by traditional GC detectors (i.e. flame ionization detector or thermal conductivity detector). Measuring how the retention time changes as a function of probe molecule chemistry, probe molecule size, probe molecule concentration, column temperature, or carrier gas flow rate can elucidate a wide range of physico-chemical properties of the solid under investigation. Several in depth reviews of IGC have been published previously.
Sources: en.wikipedia.org
=== Fencing === The sport reached its peak during the 2020 and 2024 Olympic Games. Cheung Ka-long became a national icon by winning back-to-back gold medals in men's individual foil, while Vivian Kong secured gold in women's individual épée in Paris 2024.
=== COVID-19 pandemic === Bukele issued an executive decree on 11 March 2020 imposing a "quarantine throughout the national territory" ("cuarentena en todo el territorio nacional"), shortly after World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus declared the COVID-19 outbreak a pandemic. The quarantine suspended all school activities for 21 days, prohibited foreigners from entering the country, and mandated a 30-day quarantine for everyone entering the country. Bukele confirmed the first case of COVID-19 in El Salvador on 18 March 2020. The country's first death from the disease was recorded on 31 March. On 5 May 2023, the Pan American Health Organization declared the end of the pandemic. According to the WHO, As of 27 September 2023, El Salvador had 201,807 confirmed cases of COVID-19 and 4,230 deaths from the disease by 2 June 2023; the WHO reported that 11,426,688 doses of the COVID-19 vaccine had been administered in El Salvador by that date.
Computer Games Magazine argued the futility of reviewing the game due to its episodic nature; as the first part of a three-part story arc, it is difficult to judge it when divorced from the final product. Game Revolution expressed disappointment at a lack of new features such as environments and weapons. During the 10th Annual Interactive Achievement Awards, the Academy of Interactive Arts & Sciences nominated Half-Life 2: Episode One for "First-Person Action Game of the Year".
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.